Brexit – What’s next for Life Sciences companies?

December 28, 2017

This episode was first broadcast as a webinar on 3 April 2017.

The Life Sciences lawyers Charles Brasted, Elisabethann Wright, Fabien Roy, Helen Kimberley and Sahira Khwaja will discuss:

  • What is the likely process from the serving of the Article 50 notice to the UK leaving the EU?
  • What effect might Brexit have for existing and future marketing authorisations for medicinal products?
  • How might medical device manufacturers be affected?
  • How does the decision affect commercial contracts?
  • What are the questions you should consider from an IP perspective?
  • Is there anything you should do immediately?
  • How can your businesses influence what happens next?

This episode was first broadcast as a webinar on 3 April 2017. The webinar recording is available here: http://bit.ly/2CdePdR

00:0000:00